Ask about this productRelated genes to: TMEM51 Blocking Peptide
- Gene:
- TMEM51 NIH gene
- Name:
- transmembrane protein 51
- Previous symbol:
- C1orf72
- Synonyms:
- FLJ10199
- Chromosome:
- 1p36.21
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-18
- Date modifiied:
- 2014-11-18
Related products to: TMEM51 Blocking Peptide
Related articles to: TMEM51 Blocking Peptide
- Long noncoding RNAs (lncRNAs) participate in various physiological and pathological processes of tumors and have a significant correlation with MRI radiomics. This study investigated the role of lncRNA TMEM51-AS1 in TNBC and probed the role of preoperative DCE-MRI combined with TMEM51-AS1 in risk stratification of postoperative recurrence of TNBC. Real-time quantitative PCR was used to detect the tissue TMEM51-AS1 expression after operation. According to the recurrence and metastasis of patients 1 year after surgery, patients were grouped into high-risk and low-risk groups. The value of preoperative DCE-MRI and TMEM51-AS1 in the assessment of postoperative recurrence and metastasis was analyzed using the receiver operating characteristic curve. CCK-8 and Transwell assays were performed to evaluate the influence of TMEM51-AS1 on TNBC cellular capacities. TMEM51-AS1 was decreased in TNBC tissues, especially in high-risk groups. TMEM51-AS1 expression, Max Slope, and Max Cone were risk factors associated with postoperative recurrent metastasis, and combined three had a high diagnostic value in predicting postoperative recurrent metastasis. Increased TMEM51-AS1 weakened TNBC cell proliferation, migration, and invasion by regulating miR-19a-3p. Combined preoperative DCE-MRI and TMEM51-AS1 testing may be used to predict the risk of postoperative recurrent metastasis in patients with TNBC. TMEM51-AS overexpression may repress TNBC progression by miR-19a-3p, which may guide the subsequent clinical management and improve the survival of TNBC patients. - Source: PubMed
Song TianZhu ZhenfangWu Kanhua - Prediction of incident macrovascular events (iMEs) in individuals with type 2 diabetes (T2D) remains suboptimal. We aim to discover blood-based epigenetic biomarkers predicting iMEs in 752 newly diagnosed individuals with T2D, among whom 102 developed iMEs during follow-up. 461 DNA methylation sites, e.g., near ARID3A, GATA5, HDAC4, IRS2, and TMEM51, associate with iMEs. Using cross-validation, a methylation risk score (MRS) containing 87 sites predicts iMEs with an area under the curve (AUC) of 0.81 and an AUC of 0.84 for the combination of MRS and clinical risk factors, better than SCORE2-Diabetes (Systematic Coronary Risk Evaluation 2-Diabetes), UKPDS (United Kingdom Prospective Diabetes Study), Framingham, and polygenic risk scores (AUCs = 0.54-0.62). This epigenetic biomarker has a negative predictive value of 95.9% and improves the classification of iMEs with continuous net reclassification improvement (NRI) showing 90.2% improvement versus clinical factors. Atherosclerotic versus non-atherosclerotic aortas show 78 differentially methylated sites. We validate 32 sites in EPIC-Potsdam and 43 in OPTIMED cohorts, including an MRS (AUC = 0.80). Together, blood-based epigenetic biomarkers predict iMEs better than clinical risk factors, supporting its future clinical use. - Source: PubMed
Publication date: 2025/08/07
García-Calzón SoniaMaguolo AliceEichelmann FabianEdsfeldt AndreasPerfilyev AlexanderMaziarz MarlenaLindström AxelSun JiangmingBriviba MontaSchulze Matthias BKlovins JanisAhlqvist EmmaGonçalves IsabelLing Charlotte - Colorectal cancer (CRC) is the third most common cause of death worldwide and has high mortality and a poor prognosis. Long non-coding RNAs (lncRNAs) are non-coding RNAs longer than 200 nucleotides that play roles in cancer through multiple mechanisms. TMEM51-AS1 is a newly discovered 40,650 bp lncRNA. Our results showed that TMEM51-AS1 expression was significantly downregulated in CRC tissues (fold change = 0.74, P < 0.0001). This finding was confirmed in 20 pairs of CRC carcinoma and paracancerous tissues (fold change = 0.5, P < 0.001). Additionally, TMEM51-AS1 expression was found to be significantly reduced in CRC cell lines compared to normal human intestinal epithelial cells (P < 0.001). Bioinformatic analysis revealed that TMEM51-AS1 expression was associated with immune escape, RNA methylation, and DNA damage and repair. TMEM51-AS1 may also activate energy metabolism pathways to participate in cancer development. Drug sensitivity analysis confirmed that several drugs are more effective in CRC patients with high expression of TMEM51-AS1. In conclusion, our study demonstrates that TMEM51-AS1 can suppress the progression of CRC. - Source: PubMed
Publication date: 2025/05/23
Wu DongpingXia QingSu XinmingMao YunanMao JiweiDing QiannanLiu JianjiangZhong WangyanZhang XiaoyuLi HanbingDuan Shiwei - Raynaud's syndrome is a dysautonomia where exposure to cold causes vasoconstriction and hypoxia, particularly in the extremities. We performed meta-analysis in four cohorts and discovered eight loci (ADRA2A, IRX1, NOS3, ACVR2A, TMEM51, PCDH10-DT, HLA, and RAB6C) where ADRA2A, ACVR2A, NOS3, TMEM51, and IRX1 co-localized with expression quantitative trait loci (eQTLs), particularly in distal arteries. CRISPR gene editing further showed that ADRA2A and NOS3 loci modified gene expression and in situ RNAscope clarified the specificity of ADRA2A in small vessels and IRX1 around small capillaries in the skin. A functional contraction assay in the cold showed lower contraction in ADRA2A-deficient and higher contraction in ADRA2A-overexpressing smooth muscle cells. Overall, our study highlights the power of genome-wide association testing with functional follow-up as a method to understand complex diseases. The results indicate temperature-dependent adrenergic signaling through ADRA2A, effects at the microvasculature by IRX1, endothelial signaling by NOS3, and immune mechanisms by the HLA locus in Raynaud's syndrome. - Source: PubMed
Publication date: 2024/08/13
Tervi AnniinaRamste MarkusAbner ErikCheng PaulLane Jacqueline MMaher MatthewValliere JesseLammi VilmaStrausz SatuRiikonen JuhaNguyen TrieuMartyn Gabriella ESheth Maya UXia FanDocampo Mauro LagoGu Wenduo Esko TõnuSaxena RichaPirinen MattiPalotie AarnoRipatti SamuliSinnott-Armstrong NasaDaly MarkEngreitz Jesse MRabinovitch MarleneHeckman Caroline AQuertermous ThomasJones Samuel EOllila Hanna M - Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Catheter ablation has become a crucial treatment for AF. However, there is a possibility of atrial fibrillation recurrence after catheter ablation. Our study sought to elucidate the role of lncRNA‒mRNA regulatory networks in late AF recurrence after catheter ablation. - Source: PubMed
Publication date: 2024/04/20
Tang HuaiguangLu KongmiaoWang YanShi YueMa WanshengChen XiaomengLi BingongShao Yibing